MAXCYTE, INC. Cash Flow Statement
MXCT|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
MAXCYTE, INC. used $34M in operating cash flow and negative free cash flow of $36M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$44.6M | -$37.9M | -$23.6M | -$23.6M | -$19.1M |
| Depreciation & Amortization | $4.3M | $4.2M | $2.7M | $2.7M | $1.4M |
| Operating Cash Flow | -$34.4M | -$21.7M | -$14.8M | -$14.8M | -$10.7M |
| Capital Expenditures | $1.8M | $3.7M | $18.5M | $18.5M | $3.8M |
| Free Cash Flow | -$36.2M | -$25.4M | -$33.3M | -$33.3M | -$14.5M |
| FCF Margin | -109.5% | -61.5% | -75.1% | -75.1% | -42.8% |